Top Semax Studies: The Most Influential Papers, Explained
Anyone researching Semax eventually asks the same question: which papers actually matter? This guide to the top semax studies answers it study by study — not as a themed roundup, but as a chronological walk through the individual publications that shaped what the field knows. Each of the top semax studies below gets its own summary: what the researchers did, what they reported, and why the paper still gets cited. That paper-by-paper structure is what makes this a top semax studies guide rather than a generic overview. Everything is drawn from the published record — PubMed-indexed papers, with author, year, journal, and PMID where available — and everything stays in research framing: no human-use claims, no dosage information, no medical advice.
Research-use-only disclaimer: Semax is not an FDA-approved drug and is handled as a research compound for laboratory and scientific investigation. This article summarizes published studies for educational purposes only. It contains no dosage information, no usage instructions, and no medical advice. All products on this site are sold strictly for laboratory research use.
How This Top Semax Studies List Was Built
A “top studies” list is only as honest as its selection method, so here is the method behind this top semax studies ranking: the papers below are the ones most consistently cited across reviews of the Semax literature — including the 2022 Pharmaceutics review of Russian peptide drug development and the compound’s Wikipedia reference list — plus the small set of human studies that anchor the clinical side of the record. Russian-language journals dominate the list, which is itself an important finding: Semax research has been concentrated in Russian research groups, and large independent Western replication remains limited. That context matters more than any single paper.
Reading these summaries correctly
Each summary reports what the authors published — not what the findings prove. Animal-model results do not transfer to humans, small human studies are preliminary by nature, and “reported” always means “reported by the authors.” That discipline is what separates a research guide to the top semax studies from hype.
Top Semax Studies: The Timeline
1991 — Potaman et al.: the first description
Citation: Potaman VN, Alfeeva LY, Kamensky AA, Levitzkaya NG, Nezavibatko VN. “N-terminal degradation of ACTH(4-10) and its synthetic analog semax by the rat blood enzymes.” Biochemical and Biophysical Research Communications, 1991. PMID: 1851003.
What they did: The first published description of Semax. The team compared how Semax and its parent ACTH(4-10) fragment were broken down by enzymes in rat blood, focusing on N-terminal degradation.
What they reported: The degradation profile of the new synthetic analogue relative to the natural fragment — foundational handling data for everything that followed.
Why it matters: Every research program starts with basic characterization. Without this paper there is no Semax literature at all, which earns it the first slot among the top semax studies on historical grounds alone.
1997 — Gusev et al.: acute ischemic stroke, clinical and electrophysiological
Citation: Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat’ko VN, Zhuravleva EIu, Vanichkin AV. “Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study).” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 1997. PMID: 11517472. Clinical trial.
What they did: A clinical study of Semax in the acute phase of hemispheric ischemic stroke, combining clinical assessment with electrophysiological measures.
What they reported: The authors reported effectiveness of Semax in the acute stroke period across their clinical and electrophysiological endpoints.
Why it matters: This is the earliest clinical-trial entry in the Semax record on PubMed, and it set the template for the stroke-rehabilitation research track that would define much of the compound’s clinical literature. It appears in PubMed’s clinical-trial filter for Semax — a short list, which our Semax clinical trial landscape overview examines in full.
2000 — Polunin et al.: optic nerve disease
Citation: Polunin GS, Nurieva SM, Baiandin DL, Sheremet NL, Andreeva LA. “Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease.” Vestnik Oftalmologii, 2000. PMID: 10741256. Clinical trial.
What they did: A clinical trial adding Semax to the therapeutic complex in patients with diseases of the optic nerve.
What they reported: The authors reported that adding Semax had a favorable impact on the intensity and rate of recovery in their patients.
Why it matters: One of the few non-stroke clinical applications studied in humans — it broadened the investigated indications beyond the brain-injury track and is frequently cited in reviews of the compound’s clinical history.
2005 — Eremin et al.: dopaminergic and serotonergic systems
Citation: Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research, 2005. PMID: 16362768.
What they did: Measured the effects of Semax on dopamine and serotonin systems in rodent brains.
What they reported: Activation of both dopaminergic and serotonergic brain systems in rodents — a neurochemical finding, not a behavioral claim.
Why it matters: This paper is the most-cited mechanistic anchor for Semax’s monoamine effects and a core reference in the top semax studies canon. It is also the study behind the frequently repeated (and frequently oversimplified) claim that Semax “raises dopamine and serotonin” — the paper shows system activation in rodents, which is a narrower and more careful statement.
2006 — Dolotov et al.: BDNF and TrkB in the hippocampus
Citation: Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. “Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.” Brain Research, 2006. PMID: 16996037.
What they did: Examined Semax’s effects on brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the rat hippocampus.
What they reported: Rapid regulation of BDNF and TrkB expression — the neurotrophin signaling finding most associated with Semax.
Why it matters: If one paper defines the modern Semax research narrative, this is it. The BDNF/TrkB result is cited across reviews, vendor literature, and secondary coverage alike. It is also the paper most often stretched beyond its design: a rat-hippocampus expression study is strong mechanistic evidence in its lane, not evidence of cognitive enhancement in humans. Among the top semax studies, it is the most important — and the most in need of careful reading.
2013 — Yatsenko et al.: chronic unpredictable stress
Citation: Yatsenko KA, Glazova NY, Inozemtseva LS, Andreeva LA, Kamensky AA, Grivennikov IA, et al. “Heptapeptide semax attenuates the effects of chronic unpredictable stress in rats.” Doklady Biological Sciences, 2013. PMID: 24385169.
What they did: Tested whether Semax modified the behavioral effects of chronic unpredictable stress in rats.
What they reported: Attenuation of the stress paradigm’s behavioral effects in the Semax-treated animals.
Why it matters: The stress-resilience angle connects Semax’s ACTH-fragment origins to its behavioral literature — a thematically neat paper that extended the compound’s investigated effects beyond cognition and neuroprotection into stress adaptation — enough to hold its place in this top semax studies ranking. Related behavioral work (Vilenskii et al., 2007; Volodina et al., 2012) sits in the same track.
2018 — Lebedeva et al.: resting-state fMRI in healthy volunteers
Citation: Lebedeva et al. “Effects of intranasal Semax on resting-state brain activity.” Bulletin of Experimental Biology and Medicine, 2018. (Follow-up with 52 participants comparing Semax, Selank, and placebo published 2020.)
What they did: Twenty-four healthy adults underwent resting-state fMRI before dosing and again at five and twenty minutes after intranasal Semax; fourteen received the peptide and ten received placebo.
What they reported: The Semax group showed an enlarged rostral subcomponent of the default mode network, centered on medial frontal cortex. The 2020 follow-up reported connectivity changes between the right amygdala and right temporal regions.
Why it matters: Rare human neuroimaging data on Semax — real measurements in real people, on the intranasal route, showing brain-state changes within minutes. The honest limits: small samples, a single research group, no replication, and brain-activity measures rather than cognitive-performance outcomes. Still, in any honest top semax studies assessment, it is the most direct human brain data in the literature.
2018 — Gusev et al.: ischemic stroke rehabilitation and BDNF
Citation: Gusev EI, et al. “The efficacy of semax in the treatment of patients at different stages of ischemic stroke.” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018. PMID: 29798983. Clinical trial.
What they did: Patients at early and late stages of post-stroke rehabilitation were divided into Semax-treated and control subgroups; the treated group received two courses of Semax treatment with an interval between them.
What they reported: The authors reported improved plasma BDNF levels along with better motor performance and Barthel index scores in the Semax subgroups.
Why it matters: The most recent clinical-trial entry on PubMed and the only one linking the human stroke literature back to the BDNF mechanism from Dolotov’s animal work. It closes a loop the field had left open for a decade — which is why it belongs among the top semax studies despite the usual caveats about the Russian clinical literature.
2022 — Deigin et al.: the big-picture review
Citation: Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM. “Development of Peptide Biopharmaceuticals in Russia.” Pharmaceutics, 2022. PMC 9030433, PMID: 35456550.
What they did: A peer-reviewed, English-language review of the Russian peptide drug development tradition — including Semax — published in an international open-access journal.
What they reported: A synthesis of the development history, pharmacology, and clinical positioning of Russian peptide biopharmaceuticals.
Why it matters: Much of the Semax literature sits in Russian-language journals that Western researchers rarely read. This review is the most accessible English-language entry point to the development story, and it is the paper to hand a colleague who wants the context behind the top semax studies without learning Russian.
Top Semax Studies: Summary Table
The table below compresses the top semax studies timeline into a single top semax studies reference — year, design, research focus, and the headline reported finding for each paper.
| Study | Design | Focus | Reported finding |
|---|---|---|---|
| Potaman 1991 | Enzyme degradation (rat blood) | Basic characterization | Degradation profile vs. ACTH(4-10) |
| Gusev 1997 | Clinical trial | Acute ischemic stroke | Reported effectiveness, clinical + electrophysiological |
| Polunin 2000 | Clinical trial | Optic nerve disease | Favorable impact on recovery rate |
| Eremin 2005 | Rodent neurochemistry | Monoamine systems | Dopaminergic/serotonergic activation |
| Dolotov 2006 | Rat hippocampus | Neurotrophins | BDNF and TrkB expression regulated |
| Yatsenko 2013 | Rat behavior | Chronic stress | Stress effects attenuated |
| Lebedeva 2018 | Human fMRI | Resting-state networks | Enlarged rostral default-mode subcomponent |
| Gusev 2018 | Clinical trial | Stroke rehabilitation | BDNF, motor, Barthel index improved |
| Deigin 2022 | Review | Development history | English-language synthesis of Russian peptide R&D |
What the table reveals
Three patterns stand out across the top semax studies. First, the mechanistic core (BDNF, monoamines) is animal work; the human core (stroke, optic nerve, fMRI) is small and Russian. Second, the two halves barely meet — only Gusev 2018 connects the mechanism literature to human outcomes. Third, nothing here is a large, Western, placebo-controlled trial of cognition in healthy adults. A researcher who internalizes those three patterns will read every future Semax paper correctly.
Where to Read the Papers Yourself
This top semax studies list was built from primary sources only — no secondary summaries, no invented findings. Every paper above is indexed on PubMed — search the author and year, or use the PMID from each citation. The clinical-trial subset can be browsed through PubMed’s trial filters. For the regulatory backdrop that shapes how this literature is used outside Russia, the FDA’s drug information pages explain approval status, and our Semax clinical trial landscape guide maps what trial registries do and do not contain.
For researchers who want the molecule behind the papers, our Semax 10mg research listing supplies the compound strictly for laboratory research use — and the Semax nasal spray research overview covers the intranasal format most of the human studies used. The companion primer Semax explained for beginners is the right starting point if any background above felt unfamiliar.
Top Semax Studies: Key Takeaways
The research verdict on the literature
- Nine papers carry the field: from Potaman 1991 (first description) through Deigin 2022 (English-language synthesis).
- The mechanistic anchor is Dolotov 2006 (BDNF/TrkB, rat hippocampus); the human anchors are the Gusev stroke trials and Lebedeva’s fMRI work.
- Animal mechanism work and human clinical work rarely connect — Gusev 2018 is the exception.
- The literature is concentrated in Russian research groups; large Western replication is absent.
- Every summary above reports what authors published — not proof of human efficacy.
(Research framing only — not a recommendation for human use.)
Top Semax Studies: Final Notes
The top semax studies tell a coherent story when read in order: a synthetic ACTH-fragment analogue is characterized, its neurochemical effects are mapped in animals, its clinical use develops in Russian stroke and optic-nerve medicine, human neuroimaging adds a small but real data point, and an English-language review finally makes the arc accessible. What the story lacks — large, independent, Western trials — is as informative as what it contains. For a new researcher, that is the single most useful lesson this top semax studies guide can offer: read every top semax studies claim against the primary papers: know what the literature is, and you will never mistake it for what it is not.
Top Semax Studies: Frequently Asked Questions
Quick answers to the questions researchers ask about the Semax literature.
What is the most important Semax study?
By citation impact, Dolotov et al. 2006 (Brain Research, PMID 16996037) tops this top semax studies list — the paper reporting Semax’s regulation of BDNF and TrkB expression in the rat hippocampus. It anchors the neurotrophin narrative across the top semax studies literature. Read it as strong animal-mechanism evidence, not as evidence about humans.
Are there human clinical trials of Semax?
Yes, a small number, all Russian: Gusev et al. 1997 and 2018 in ischemic stroke, Polunin et al. 2000 in optic nerve disease, and Kurysheva et al. 2001 in glaucomatous optic neuropathy. They appear in PubMed’s clinical-trial filter for Semax. Our Semax clinical trial landscape guide examines the registry picture in detail.
Has Semax been studied with brain imaging in humans?
Yes — Lebedeva et al. 2018 used resting-state fMRI in 24 healthy volunteers (14 Semax, 10 placebo) and reported an enlarged rostral default-mode subcomponent after intranasal Semax; a 2020 follow-up with 52 participants compared Semax, Selank, and placebo. Small, single-group, unreplicated — but real human neuroimaging data.
Where can I read the full papers?
All nine of the top semax studies are indexed on PubMed under their author, year, and PMID citations above — which is how any top semax studies claim should be checked. Deigin et al. 2022 is open access via PMC (PMC 9030433). Several older Russian-journal papers have English abstracts with full text in Russian.
Why are most Semax studies Russian?
Semax was developed at Russia’s Institute of Molecular Genetics and became a Russian prescription medicine, so its research program grew inside Russian institutions and journals. Western pharmaceutical development never picked it up — there was no patent-driven incentive — which is why the top semax studies list looks the way it does.
Where can researchers source Semax for laboratory use?
For laboratory research use, see our Semax 10mg research listing. All products on this site are sold strictly for laboratory research use. Nothing here recommends human use.
1 Comment